All Stories

  1. Neurocognitive Recovery After Liver Transplantation Is Driven by Metabolite-mediated Reactivation of Cortical Networks

    Article • Transplantation, August 2026, Wolters Kluwer Health

    Björn Nashan

  2. The Role of mTOR Inhibitors in CMV Prevention: An Overlooked Aspect of the Fourth International CMV Consensus Guidelines

    Article • Transplantation, July 2026, Wolters Kluwer Health

    Björn Nashan

  3. Development and Preliminary Validation of a Quality of Life Scale for Living Solid Organ Donors

    Article • Western Journal of Nursing Research, April 2026, SAGE Publications

    Björn Nashan

  4. Standardized Management Pathway to Prevent Acute Rejection After Liver Transplantation Following ICI Therapy for Downstaging HCC

    Article • Health Care Science, April 2026, Tsinghua University Press

    Björn Nashan

  5. A Blind Spot in Post‐Liver Transplant Care: Correlation and Causation in Immunosuppression, Drug Monitoring, and Immune Checkpoint Inhibitor‐Related Rejection

    Article • Health Care Science, April 2026, Tsinghua University Press

    Björn Nashan

  6. Pediatric Organ Transplantation in China

    Article • Pediatric Transplantation, April 2026, Wiley

    Björn Nashan

  7. Targeting NK cell CLEC12B enhances cancer immunotherapy

    Article • Nature Immunology, March 2026, Springer Science + Business Media

    Björn Nashan

  8. A Case Report of Posterior Reversible Encephalopathy Syndrome With Intracranial Hemorrhage After Split-Liver Transplantation

    Article • Transplantation Proceedings, March 2026, Elsevier

    Björn Nashan

  9. Legal Framework on Organ Donation and Transplantation in China

    Article • Transplantation, February 2026, Wolters Kluwer Health

    Björn Nashan

  10. De novo schizophrenia after liver transplantation: A case report

    Article • World Journal of Hepatology, January 2026, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Björn Nashan

  11. SAMSN1 restrains NK cell mediated anti-tumor immunity in hepatocellular carcinoma

    Article • Nature Communications, January 2026, Springer Science + Business Media

    Björn Nashan

  12. The First Clinical Renal Xenotransplantation Study (EXPAND): Evaluating Safety, Function, and Zoonotic Risks

    Article • Health Care Science, December 2025, Tsinghua University Press

    Björn Nashan

  13. Acute liver failure caused by alkaloids from traditional Chinese medicine: A case report

    Article • World Journal of Hepatology, October 2025, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Björn Nashan

  14. Lung Xenotransplantation

    Article • Health Care Science, October 2025, Tsinghua University Press

    Björn Nashan

  15. Efficacy and Safety of Different Doses of Bevacizumab Combined with Atezolizumab in Unresectable Hepatocellular Carcinoma

    Article • Journal of Hepatocellular Carcinoma, August 2025, Taylor & Francis

    Björn Nashan

  16. Proteomic Landscape of Colorectal Cancer Derived Liver Metastasis Reveals Three Distinct Phenotypes With Specific Signaling and Enhanced Survival

    Article • Molecular & Cellular Proteomics, August 2025, Elsevier

    Björn Nashan

  17. Author Correction: Spatial immune scoring system predicts hepatocellular carcinoma recurrence

    Article • Nature, July 2025, Springer Science + Business Media

    Björn Nashan

  18. Efficacy of salvage surgery for hepatocellular carcinoma following conversion therapy

    Article • World Journal of Clinical Oncology, June 2025, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Björn Nashan

  19. Enhanced recovery after liver transplantation—a prospective analysis focusing on quality assessment

    Article • HepatoBiliary Surgery and Nutrition, June 2025, AME Publishing Company

    Björn Nashan

  20. Biomarker, efficacy and safety analysis of transcatheter arterial chemoembolization combined with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma

    Article • Medical Oncology, May 2025, Springer Science + Business Media

    Björn Nashan

  21. Spatial immune scoring system predicts hepatocellular carcinoma recurrence

    Article • Nature, March 2025, Springer Science + Business Media

    Björn Nashan

  22. Organ donation in Germany: opt-in vs. opt-out—opinions and voting patterns in the 19th German Bundestag

    Article • Frontiers in Transplantation, February 2025, Frontiers

    Björn Nashan

  23. Comparison of 2 Different Types of Arterial and Biliary Anastomoses While Preserving the Gastroduodenal Artery: A Retrospective Study

    Article • Transplantation Proceedings, December 2024, Elsevier

    Björn Nashan

  24. Suppression of Hepatocyte Ferroptosis via USP19‐Mediated Deubiquitination of SLC7A11 in Ischemia‐Free Liver Transplantation

    Article • Advanced Science, November 2024, Wiley

    Björn Nashan

  25. Incidence and Treatment of Arginine Vasopressin Deficiency (Central Diabetes Insipidus) in the Setting of Brain Death and Associations with Renal Function and Hemodynamics in Organ Donors

    Article • Journal of Clinical Medicine, November 2024, MDPI AG

    Björn Nashan

  26. Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study

    Article • Arabian archaeology and epigraphy, October 2024, Elsevier

    Björn Nashan, Professor shu hua zhang

  27. Establishing a New Liver Transplant Unit in China—First Affiliated Hospital of the University of Science and Technology of China, Hefei, Anhui, People’s Republic of China

    Article • Transplantation, September 2024, Wolters Kluwer Health

    Björn Nashan

  28. Liver protects neuron viability and electrocortical activity in post-cardiac arrest brain injury

    Article • EMBO Molecular Medicine, September 2024, Springer Science + Business Media

    Björn Nashan

  29. Diagnosis and Treatment of Hepatic Hematoma After Liver Transplantation in a Timely Manner

    Article • Transplantation Proceedings, July 2024, Elsevier

    Björn Nashan

  30. In Vitro Profiling of Commonly Used Post-transplant Immunosuppressants Reveals Distinct Impact on Antiviral T-cell Immunity Towards CMV

    Article • Transplant International, April 2024, Frontiers

    Björn Nashan

  31. The German Transplant Certification

    Article • HepatoBiliary Surgery and Nutrition, April 2024, AME Publishing Company

    Björn Nashan

  32. Rebuttal to the author's reply - The German Transplantation Scandal

    Article • Journal of Liver Transplantation, February 2024, Elsevier

    Björn Nashan

  33. Assessment and Evaluation for Patients With Alcohol Use Disorder: The German Allocation Policy

    Article • Transplantation, December 2023, Wolters Kluwer Health

    Björn Nashan

  34. Liver Protects Cytoarchitecture, Neuron Viability and Electrocortical Activity in Post-Cardiac Arrest Brain Injury

    Article • December 2023, openRxiv

    Björn Nashan

  35. Influence of immunosuppressive drugs on natural killer cells in therapeutic drug exposure in liver transplantation

    Article • HepatoBiliary Surgery and Nutrition, December 2023, AME Publishing Company

    Björn Nashan

  36. Impact of everolimus plus calcineurin inhibitor on formation of non-HLA antibodies and graft outcomes in kidney transplant recipients: 12-month results from the ATHENA substudy

    Article • Frontiers in Transplantation, November 2023, Frontiers

    Björn Nashan

  37. The German transplantation scandal – The missing references

    Article • Journal of Liver Transplantation, November 2023, Elsevier

    Björn Nashan

  38. Everolimus plus reduced calcineurin inhibitor prevents de novo anti-HLA antibodies and humoral rejection in kidney transplant recipients: 12-month results from the ATHENA study

    Article • Frontiers in Transplantation, October 2023, Frontiers

    Björn Nashan

  39. Prevalence and factors associated with depression and anxiety in living liver donors: A systematic review and meta-analysis

    Article • Journal of Psychosomatic Research, October 2023, Elsevier

    Björn Nashan

  40. Identification and validation of Birc5 as a novel activated cell cycle program biomarker associated with infiltration of immunosuppressive myeloid‐derived suppressor cells in hepatocellular carcinoma

    Article • Cancer Medicine, June 2023, Wiley

    Björn Nashan

  41. Retroperitoneal Laparoscopic Hepatectomy for a Subcapsular Hepatocellular Carcinoma in Segment VI (Video)

    Article • Annals of Surgical Oncology, May 2023, Springer Science + Business Media

    Björn Nashan

  42. Systematic characterization of chromodomain proteins reveals an H3K9me1/2 reader regulating aging in C. elegans

    Article • Nature Communications, March 2023, Springer Science + Business Media

    Björn Nashan

  43. Entecavir Combined With Short-term Hepatitis B Immunoglobulin in Preventing Hepatitis B Virus Recurrence in Liver Transplant Recipients

    Article • Transplantation Proceedings, March 2023, Elsevier

    Björn Nashan

  44. Human Leucocyte Antigen–Matching Can Improve Long Term Outcome of Renal Allografts from Donors Older Than 75 Years

    Article • Transplantation Proceedings, March 2023, Elsevier

    Björn Nashan

  45. Involvement of endoplasmic reticulum stress in rifampicin-induced liver injury

    Article • Frontiers in Pharmacology, October 2022, Frontiers

    Björn Nashan

  46. Clinical efficacy of avatrombopag and recombinant human thrombopoietin in the treatment of chronic liver disease-associated severe thrombocytopenia: A real-world study

    Article • Frontiers in Pharmacology, October 2022, Frontiers

    Björn Nashan

  47. The SNAPc complex mediates starvation-induced trans-splicing in Caenorhabditis elegans

    Article • Journal of Genetics and Genomics, October 2022, Elsevier

    Björn Nashan

  48. Incidence of Ischemia Reperfusion Injury Related Biliary Complications in Liver Transplantation: Effect of Different Types of Donors

    Article • Transplantation Proceedings, September 2022, Elsevier

    Björn Nashan

  49. Systematic characterization of chromodomain proteins reveals an H3K9me1/2 reader regulating aging in C. elegans

    Article • August 2022, openRxiv

    Björn Nashan

  50. Panoramic comparison between NK cells in healthy and cancerous liver through single-cell RNA sequencing

    Article • Cancer Biology and Medicine, July 2022, Tsinghua University Press

    Björn Nashan

  51. Porcine cytomegalovirus in xenotransplantation: The new frontier in human transplantation?

    Article • Health Care Science, July 2022, Wiley

    Björn Nashan

  52. Combined Targeting of AKT and mTOR Inhibits Tumor Formation of EpCAM+ and CD90+ Human Hepatocellular Carcinoma Cells in an Orthotopic Mouse Model

    Article • Cancers, April 2022, MDPI AG

    Björn Nashan

  53. Risk factors of perioperative complications and management with enhanced recovery after primary surgery in women with epithelial ovarian carcinoma in a single center

    Article • Oncology Letters, March 2022, Spandidos Publications

    Björn Nashan

  54. Postmortem high-dimensional immune profiling of severe COVID-19 patients reveals distinct patterns of immunosuppression and immunoactivation

    Article • Nature Communications, January 2022, Springer Science + Business Media

    Björn Nashan

  55. Liver Transplantation Reverses Hepatic Myelopathy in Hepatitis B-Related Decompensated Liver Cirrhosis: Case Report and Review of the Literature

    Article • Transplantation Proceedings, January 2022, Elsevier

    Björn Nashan

  56. Diagnostic and Prognostic Significances of SOX9 in Thymic Epithelial Tumor

    Article • Frontiers in Oncology, October 2021, Frontiers

    Björn Nashan

  57. Early Everolimus‐Facilitated Reduced Tacrolimus in Liver Transplantation: Results From the Randomized HEPHAISTOS Trial

    Article • Liver Transplantation, October 2021, Wolters Kluwer Health

    Björn Nashan

  58. Successful, Combined Long-term Treatment of Cerebral Candidiasis and Aspergillosis in a Liver Transplant Recipient: A Case Report

    Article • Transplantation Proceedings, October 2021, Elsevier

    Björn Nashan

  59. Preformed T cell alloimmunity and HLA eplet mismatch to guide immunosuppression minimization with tacrolimus monotherapy in kidney transplantation: Results of the CELLIMIN trial

    Article • Arabian archaeology and epigraphy, August 2021, Elsevier

    Björn Nashan

  60. Innate lymphoid cells and cancer: Role in tumor progression and inhibition

    Article • European Journal of Immunology, July 2021, Wiley

    Björn Nashan

  61. An Orthotopic Liver Transplantation Patient Survived Without Hepatic Artery Flow Due to Thrombosis: A Case Report

    Article • Transplantation Proceedings, May 2021, Elsevier

    Björn Nashan

  62. C20orf204, a hepatocellular carcinoma-specific protein interacts with nucleolin and promotes cell proliferation

    Article • Oncogenesis, March 2021, Springer Science + Business Media

    Björn Nashan

  63. Effect of everolimus‐based drug regimens on CMV‐specific T‐cell functionality after renal transplantation: 12‐month ATHENA subcohort‐study results

    Article • European Journal of Immunology, December 2020, Wiley

    Björn Nashan

  64. CD28 gene polymorphisms and acute cellular rejection after liver transplantation

    Article • Human Immunology, December 2020, Elsevier

    Björn Nashan

  65. Is It Feasible to Standardize a Composite Postoperative Complication Reporting System for Liver Resection?

    Article • Journal of Gastrointestinal Surgery, December 2020, Elsevier

    Björn Nashan

  66. 228 Risk factors for preoperative complications and management with enhanced recovery after primary surgery for women with epithelial ovarian cancer in a single center of china

    Article • International Journal of Gynecological Cancer, December 2020, Elsevier

    Björn Nashan

  67. Liver Transplantation in a Patient With Acute-on-Chronic Liver Failure Due to Traditional Chinese Medicine Intoxication Using Donation After Circulatory Death From a Renal Transplant Recipient: A Case Report

    Article • Transplantation Proceedings, November 2020, Elsevier

    Björn Nashan

  68. Sequential metastasis to the liver and pancreas 4 years after gestational trophoblastic neoplasia: a case report

    Article • Journal of International Medical Research, November 2020, SAGE Publications

    Björn Nashan

  69. Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer

    Article • Clinical & Experimental Metastasis, October 2020, Springer Science + Business Media

    Björn Nashan

  70. ATHENA VS HEPHAISTOS - ARE DISCONTINUATION RATES IN MULTICENTER STUDIES DRIVEN BY FACTS OR ATTITUDES?

    Article • Transplantation, September 2020, Wolters Kluwer Health

    Björn Nashan

  71. Transplantation of a single kidney from pediatric donors less than 10 kg to children with poor access to transplantation: a two-year outcome analysis

    Article • BMC Nephrology, July 2020, Springer Science + Business Media

    Björn Nashan

  72. Novel coronavirus (SARS-CoV-2) infection in a renal transplant recipient: Case report

    Article • Arabian archaeology and epigraphy, July 2020, Elsevier

    Björn Nashan

  73. Incidence and potential predictors of thromboembolic events in epithelial ovarian carcinoma patients during perioperative period

    Article • European Journal of Surgical Oncology, May 2020, Elsevier

    Björn Nashan

  74. Ectonucleoside triphosphate diphosphohydrolase 1 and 5′‐nucleotidase ecto gene polymorphisms and acute cellular rejection after liver transplantation

    Article • HLA, April 2020, Wiley

    Björn Nashan

  75. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older

    Article • European Journal of Gynaecological Oncology, January 2020, MRE Press

    Björn Nashan

  76. Protein tyrosine phosphatase non‐receptor type 22 (PTPN22) gene polymorphisms in liver transplant donors and impact on acute cellular liver transplant rejection

    Article • HLA, December 2019, Wiley

    Björn Nashan

  77. Structured introduction of retroperitoneoscopic donor nephrectomy provides a high level of safety and reduces the physical burden for the donor compared to an anterior mini incision: A cohort study

    Article • International Journal of Surgery, September 2019, Wolters Kluwer Health

    Björn Nashan

  78. De novo mutations in mitochondrial DNA of iPSCs produce immunogenic neoepitopes in mice and humans

    Article • Nature Biotechnology, August 2019, Springer Science + Business Media

    Björn Nashan

  79. Effects of LncRNA Lnc-LIF-AS on cell proliferation, migration and invasion in a human cervical cancer cell line

    Article • Cytokine, August 2019, Elsevier

    Björn Nashan

  80. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients

    Article • Kidney International, July 2019, Elsevier

    Björn Nashan

  81. CD49a Expression Identifies a Subset of Intrahepatic Macrophages in Humans

    Article • Frontiers in Immunology, June 2019, Frontiers

    Björn Nashan

  82. The incidence and severity of post-hepatectomy bile leaks is affected by surgical indications, preoperative chemotherapy, and surgical procedures

    Article • HepatoBiliary Surgery and Nutrition, April 2019, AME Publishing Company

    Björn Nashan

  83. Accuracy of Pretransplant Imaging Diagnostic for Hepatocellular Carcinoma: A Retrospective German Multicenter Study

    Article • Canadian Journal of Gastroenterology and Hepatology, March 2019, Hindawi Publishing Corporation

    Marieke van Rosmalen, Björn Nashan

  84. Donor derived HLA-G polymorphisms have a significant impact on acute rejection in kidney transplantation

    Article • Human Immunology, March 2019, Elsevier

    Björn Nashan

  85. Reduced Opioid-Demand and Fewer Pulmonary Complications after Laparoscopic Liver Resection in the Posterior Segments

    Article • Digestive Surgery, February 2019, Karger Publishers

    Björn Nashan

  86. Impact of TBX21, GATA3, and FOXP3 gene polymorphisms on acute cellular rejection after liver transplantation

    Article • HLA, January 2019, Wiley

    Björn Nashan

  87. Analysis of Risk Factors for Allograft Outcome Comparing 2 Kidneys From the Same Donor in Separate Recipients

    Article • Transplantation Proceedings, December 2018, Elsevier

    Björn Nashan

  88. Dual antibody induction and de novo use of everolimus enable low-dose tacrolimus with early corticosteroid withdrawal in simultaneous pancreas-kidney transplantation

    Article • Transplant Immunology, October 2018, Elsevier

    Björn Nashan

  89. CD40 Inhibition with CFZ533 - A New, Fully Human, Non-Depleting, Fc Silent mAB - Improves Renal Allograft Function While Demonstrating Comparable Efficacy vs. Tacrolimus in De-Novo CNI-Free Kidney Transplant Recipients

    Article • Transplantation, July 2018, Wolters Kluwer Health

    Björn Nashan

  90. Limited impact of pre-existing donor specific HLA-antibodies (DSA) on long term allograft survival after first adult liver transplantation

    Article • Human Immunology, July 2018, Elsevier

    Björn Nashan

  91. Outcomes on Allograft Function after 12 Months with Everolimus Plus either Tacrolimus or Cyclosporine Compared to a Standard Tacrolimus-MPA Regimen in De Novo Renal Transplant Recipients

    Article • Transplantation, July 2018, Wolters Kluwer Health

    Björn Nashan

  92. Significant Anti-CMV/BKV Effect of a Modern Everolimus-Based Regimen Comparted to Standard Tacrolimus-MPA Regimen in de Novo Kidney Transplant Recipients

    Article • Transplantation, July 2018, Wolters Kluwer Health

    Björn Nashan

  93. The Athena Study

    Article • Transplantation, July 2018, Wolters Kluwer Health

    Björn Nashan

  94. Segment 5 parenchymal sparing in extended left hepatectomy with respect to venous outflow—is it a feasible procedure?

    Article • Langenbeck s Archives of Surgery, June 2018, Springer Science + Business Media

    Björn Nashan

  95. Outcome following right-extended split liver transplantation in the recent transplant era: Single-center analysis of a German transplant center

    Article • Clinical Transplantation, June 2018, Wiley

    Björn Nashan

  96. Obstruction of peritoneal dialysis catheter is associated with catheter type and independent of omentectomy: A comparative data analysis from a transplant surgical and a pediatric surgical department

    Article • Journal of Pediatric Surgery, April 2018, Elsevier

    Björn Nashan

  97. Reply to

    Article • Annals of Surgery, April 2018, Wolters Kluwer Health

    Björn Nashan

  98. Defining Benchmarks in Liver Transplantation

    Article • Annals of Surgery, March 2018, Wolters Kluwer Health

    Björn Nashan

  99. Long-term follow-up after full-split liver transplantation and its applicability in the recent transplant era

    Article • Clinical Transplantation, February 2018, Wiley

    Björn Nashan

  100. The Authors’ Reply

    Article • Transplantation, February 2018, Wolters Kluwer Health

    Björn Nashan

  101. mTOR Inhibition and Clinical Transplantation

    Article • Transplantation, February 2018, Wolters Kluwer Health

    Björn Nashan

  102. Limited impact of pre-existing donor specific HLA antibodies on long term survival after first adult liver transplantation

    Article • Zeitschrift für Gastroenterologie, January 2018, Thieme Publishing Group

    Björn Nashan

  103. The killer cell lectin-like receptor B1 (KLRB1) 503T>C polymorphism (rs1135816) and acute rejection after liver transplantation

    Article • HLA, December 2017, Wiley

    Björn Nashan

  104. Chronic pancreatitis in patients with liver cirrhosis negatively affects graft survival after liver transplantation

    Article • Pancreatology, November 2017, Elsevier

    Björn Nashan

  105. S2k Leitlinie Autoimmune Lebererkrankungen

    Article • Zeitschrift für Gastroenterologie, November 2017, Thieme Publishing Group

    Björn Nashan

  106. Cardiovascular Parameters to 2 years After Kidney Transplantation Following Early Switch to Everolimus Without Calcineurin Inhibitor Therapy

    Article • Transplantation, October 2017, Wolters Kluwer Health

    Björn Nashan

  107. Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection

    Article • Oncotarget, September 2017, Impact Journals, LLC

    Björn Nashan

  108. Polymorphisms of the human platelet antigen-1, -2, -3, -5, and -15 systems and acute cellular liver transplant rejection

    Article • Human Immunology, September 2017, Elsevier

    Björn Nashan

  109. Proliferative capacity exhibited by human liver-resident CD49a+CD25+ NK cells

    Article • PLOS One, August 2017, PLOS

    Björn Nashan

  110. Hobit expression by a subset of human liver-resident CD56bright Natural Killer cells

    Article • Scientific Reports, July 2017, Springer Science + Business Media

    Björn Nashan

  111. The first case of domino‐split‐liver transplantation in maple syrup urine disease

    Article • Pediatric Transplantation, June 2017, Wiley

    Björn Nashan

  112. Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study

    Article • PLoS Medicine, April 2017, PLOS

    Björn Nashan

  113. Outcome and natural course of renal dysfunction in liver transplant recipients with severely impaired kidney function prior to transplantation

    Article • United European Gastroenterology Journal, April 2017, Wiley

    Björn Nashan

  114. Improved detection of alcohol consumption using the novel marker phosphatidylethanol in the transplant setting: results of a prospective study

    Article • Transplant International, April 2017, Frontiers

    Björn Nashan

  115. Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial

    Article • Arabian archaeology and epigraphy, February 2017, Wiley

    Dr Sundar Sankaran, Björn Nashan

  116. Transplantation in Germany

    Article • Transplantation, February 2017, Wolters Kluwer Health

    Björn Nashan

  117. High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection

    Article • BMC Cancer, January 2017, Springer Science + Business Media

    Björn Nashan

  118. EpCAM-positive circulating tumor cells as liquid biomarker for early micrometastases and HCC recurrence risk

    Article • Journal of Hepatology, January 2017, Elsevier

    Björn Nashan

  119. Factors associated with long-term survival after liver transplantation: A retrospective cohort study

    Article • World Journal of Hepatology, January 2017, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Björn Nashan

  120. The influence of PEEP and positioning on central venous pressure and venous hepatic hemodynamics in patients undergoing liver resection

    Article • Journal of Clinical Monitoring and Computing, December 2016, Springer Science + Business Media

    Björn Nashan

  121. 14-bp ins/del polymorphism and +3142C>G SNP of the HLA-G gene have a significant impact on acute rejection after liver transplantation

    Article • Human Immunology, December 2016, Elsevier

    Björn Nashan

  122. Treatment with MAPKAP2 (MK2) inhibitor and DNA methylation inhibitor, 5-aza dC, synergistically triggers apoptosis in hepatocellular carcinoma (HCC) via tristetraprolin (TTP)

    Article • Cellular Signalling, December 2016, Elsevier

    Björn Nashan

  123. Incidence of BK polyomavirus infection after kidney transplantation is independent of type of immunosuppressive therapy

    Article • Transplant Infectious Disease, November 2016, Wiley

    Björn Nashan

  124. DAMP-Induced Allograft and Tumor Rejection: The Circle Is Closing

    Article • Arabian archaeology and epigraphy, September 2016, Wiley

    Abhishek Garg, PhD Ilse Daehn Daehn, Björn Nashan

  125. Prediction, prevention, and management of delayed graft function: where are we now?

    Article • Clinical Transplantation, September 2016, Wiley

    Björn Nashan

  126. Surgical complications after peritoneal dialysis catheter implantation depend on children's weight

    Article • Journal of Pediatric Surgery, August 2016, Elsevier

    Björn Nashan

  127. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re‐infection after liver transplantation

    Article • Transplant Infectious Disease, May 2016, Wiley

    Björn Nashan

  128. Extracellular-signal regulated kinase (Erk1/2), mitogen-activated protein kinase-activated protein kinase 2 (MK2) and tristetraprolin (TTP) comprehensively regulate injury-induced immediate early gene (IEG) response in in vitro liver organ culture

    Article • Cellular Signalling, May 2016, Elsevier

    Björn Nashan

  129. Selection and use of immunosuppressive therapies after liver transplantation: current German practice

    Article • Clinical Transplantation, March 2016, Wiley

    Björn Nashan

  130. Effects of FTY720 on peripheral blood lymphocytes and graft infiltrating cells in a rat model of chronic renal allograft rejection

    Article • Transplant Immunology, March 2016, Elsevier

    Björn Nashan

  131. Design and rationale of the ATHENA study – A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant pa...

    Article • Trials, February 2016, Springer Science + Business Media

    Björn Nashan

  132. Early Initiation of Everolimus After Liver Transplantation: A Single-Center Experience

    Article • Annals of Transplantation, February 2016, International Scientific Literature

    Björn Nashan

  133. High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System: success or waste of organs? The Eurotransplant 15-year all-centre survey

    Article • Nephrology Dialysis Transplantation, February 2016, Oxford University Press (OUP)

    Björn Nashan

  134. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid

    Article • Transplant Infectious Disease, February 2016, Wiley

    Björn Nashan

  135. Course of hepatitis C virus (HCV) RNA and HCV core antigen testing are predictors for reaching sustained virologic response in liver transplant recipients undergoing sofosbuvir treatment in a real‐life setting

    Article • Transplant Infectious Disease, January 2016, Wiley

    Björn Nashan

  136. Downregulation of AKT3 Increases Migration and Metastasis in Triple Negative Breast Cancer Cells by Upregulating S100A4

    Article • PLOS One, January 2016, PLOS

    Björn Nashan

  137. Associating liver partition and portal vein ligation for staged hepatectomy: From technical evolution to oncological benefit

    Article • World Journal of Gastrointestinal Surgery, January 2016, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Björn Nashan

  138. Avoid “All-Touch” by Hybrid ALPPS to Achieve Oncological Efficacy

    Article • Annals of Surgery, January 2016, Wolters Kluwer Health

    Björn Nashan

  139. Viral Hepatitis and Its Complications: Management of Hepatocellular Carcinoma

    Article • Visceral Medicine, January 2016, Karger Publishers

    Björn Nashan

  140. Regarding “Compared Efficacy of Preservation Solutions in Liver Transplantation: A Long-Term Graft Outcome Study From the European Liver Transplant Registry”

    Article • Arabian archaeology and epigraphy, December 2015, Elsevier

    Björn Nashan

  141. Depletion of three combined THOC5 mRNA export protein target genes synergistically induces human hepatocellular carcinoma cell death

    Article • Oncogene, November 2015, Springer Science + Business Media

    Björn Nashan

  142. Definition of Chronic Hepatitis E After Liver Transplant Conforms to Convention

    Article • Arabian archaeology and epigraphy, November 2015, Elsevier

    Björn Nashan

  143. Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion

    Article • Cellular Signalling, November 2015, Elsevier

    Björn Nashan

  144. De novo mTOR inhibitor‐based immunosuppression in ABO‐incompatible kidney transplantation

    Article • Clinical Transplantation, October 2015, Wiley

    Björn Nashan

  145. Anterior vertical mini‐incision vs. retroperitoneoscopic nephrectomy in living kidney donation: a prospective study on donors' quality of life and clinical outcome

    Article • Clinical Transplantation, October 2015, Wiley

    Björn Nashan

  146. Rat renal transplant model for mixed acute humoral and cellular rejection: Weak correlation of serum cytokines/chemokines with intragraft changes

    Article • Transplant Immunology, October 2015, Elsevier

    Björn Nashan

  147. Long-term Clinical Relevance of De Novo Donor-Specific Antibodies After Pediatric Liver Transplantation

    Article • Transplantation, September 2015, Wolters Kluwer Health

    Björn Nashan

  148. Role of the Fyn −93A>G polymorphism (rs706895) in acute rejection after liver transplantation

    Article • Human Immunology, September 2015, Elsevier

    Björn Nashan

  149. Determination of Ethyl Glucuronide in Hair for Detection of Alcohol Consumption in Patients After Liver Transplantation

    Article • Therapeutic Drug Monitoring, August 2015, Wolters Kluwer Health

    Björn Nashan

  150. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial

    Article • BMC Cancer, July 2015, Springer Science + Business Media

    Björn Nashan

  151. Relevance of chronic hepatitis E in liver transplant recipients: a real‐life setting

    Article • Transplant Infectious Disease, July 2015, Wiley

    Björn Nashan

  152. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1): A randomized, multidisciplinary, multinational phase III trial.

    Article • Journal of Clinical Oncology, May 2015, American Society of Clinical Oncology (ASCO)

    Björn Nashan

  153. Inhibition of AKT3 to increase migration and metastasis by upregulation of S100A4 protein expression.

    Article • Journal of Clinical Oncology, May 2015, American Society of Clinical Oncology (ASCO)

    Björn Nashan

  154. Everolimus and sirolimus in transplantation-related but different

    Article • Expert Opinion on Drug Safety, April 2015, Taylor & Francis

    Björn Nashan

  155. A German survey of the abdominal transplantation surgical work force

    Article • Transplant International, April 2015, Frontiers

    Björn Nashan

  156. P1310 : Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1) – a randomized, multidisciplinary, multinational phase III ...

    Article • Journal of Hepatology, April 2015, Elsevier

    Björn Nashan

  157. P0748 : Course of HCV RNA and HCV core antigen testing are predictors for reaching SVR in transplant recipients

    Article • Journal of Hepatology, April 2015, Elsevier

    Björn Nashan

  158. P1320 : Early everolimus-based tacrolimus reduction in de novo liver transplant recipients: Design and baseline data from Hephaistos study

    Article • Journal of Hepatology, April 2015, Elsevier

    Björn Nashan

  159. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial

    Article • Trials, March 2015, Springer Science + Business Media

    Björn Nashan

  160. High B‐cell activating factor is not associated with worse 3‐year graft outcome in blood group‐incompatible kidney transplantation with rituximab induction

    Article • Clinical Transplantation, February 2015, Wiley

    Björn Nashan

  161. Surgical complications after kidney transplantation: different impacts of immunosuppression, graft function, patient variables, and surgical performance

    Article • Clinical Transplantation, February 2015, Wiley

    Björn Nashan

  162. Association Between a Gain-of-Function Variant of PTPN22 and Rejection in Liver Transplantation

    Article • Transplantation, February 2015, Wolters Kluwer Health

    Björn Nashan

  163. Is There a Role for Liver Transplantation in Non-Colorectal Liver Metastases?

    Article • Visceral Medicine, January 2015, Karger Publishers

    Björn Nashan

  164. Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma

    Article • Journal of Cancer, January 2015, Ivyspring International Publisher

    Björn Nashan

  165. Surgical procedures and postsurgical tissue processing significantly affect expression of genes and EGFR-pathway proteins in colorectal cancer tissue

    Article • Oncotarget, November 2014, Impact Journals, LLC

    Björn Nashan

  166. Lack of association between CD40 polymorphisms and acute rejection in German liver transplant recipients

    Article • Human Immunology, November 2014, Elsevier

    Björn Nashan

  167. The Diagnosis and Treatment of Cholangiocarcinoma

    Article • Deutsches Ärzteblatt international, October 2014, Deutscher Arzte-Verlag GmbH

    Björn Nashan

  168. mTOR Inhibitors and their Role in Modern Concepts of Immunosuppression

    Article • Extremophiles, August 2014, Wiley

    Björn Nashan

  169. Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors

    Article • Investigational New Drugs, August 2014, Springer Science + Business Media

    Björn Nashan

  170. Polymorphism in NFKBIA gene is associated with recurrent acute rejections in liver transplant recipients

    Article • Tissue Antigens, August 2014, Wiley

    Björn Nashan

  171. Belatacept-Based Immunosuppression in De Novo Liver Transplant Recipients: 1-Year Experience From a Phase II Randomized Study

    Article • Arabian archaeology and epigraphy, August 2014, Elsevier

    Björn Nashan

  172. Developments in pediatric liver transplantation since implementation of the new allocation rules in Eurotransplant

    Article • Clinical Transplantation, July 2014, Wiley

    Björn Nashan

  173. Abdominal Closure in Oversized Pediatric Liver Transplantation - Description and Analysis of a Technique With Step Wise Reduced Patch.

    Article • Transplantation, July 2014, Wolters Kluwer Health

    Björn Nashan

  174. Effects of B-Cell Depletion in a Rat Renal Transplant Model With Exclusive MHC-Incompatibility.

    Article • Transplantation, July 2014, Wolters Kluwer Health

    Björn Nashan

  175. Risk Factors, Treatment Algorithm and Long-Term Outcome of Hepatic Artery Thrombosis in Pediatric Liver Transplantation.

    Article • Transplantation, July 2014, Wolters Kluwer Health

    Björn Nashan

  176. Outcome of liver re‐transplantation in children—Impact and special analysis of early re‐transplantation

    Article • Pediatric Transplantation, May 2014, Wiley

    Björn Nashan

  177. The role of mammalian target of rapamycin inhibitors in the management of post‐transplant malignancy

    Article • Clinical Transplantation, April 2014, Wiley

    Björn Nashan

  178. P875 FIRST CASE REPORT OF A PATIENT WITH FIBROSING CHOLESTATIC HEPATITIS C AFTER LIVER TRANSPLANTATION TREATED WITH SOFOSBUVIR AND SIMEPREVIR

    Article • Journal of Hepatology, April 2014, Elsevier

    Björn Nashan

  179. P886 RELEVANCE OF CHRONIC HEPATITIS E IN LIVER TRANSPLANT RECIPIENTS: A REAL-LIFE-SETTING

    Article • Journal of Hepatology, April 2014, Elsevier

    Björn Nashan

  180. Donor Quality of Life up to Two Years After Living Donor Liver Transplantation

    Article • Transplantation, March 2014, Wolters Kluwer Health

    Björn Nashan

  181. The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence

    Article • Journal of Transplantation, January 2014, Hindawi Publishing Corporation

    Björn Nashan

  182. Cognitive Performance in Pediatric Liver Transplant Recipients

    Article • Arabian archaeology and epigraphy, November 2013, Elsevier

    Björn Nashan

  183. A formula to calculate the standard liver volume in children and its application in pediatric liver transplantation

    Article • Transplant International, October 2013, Frontiers

    Björn Nashan

  184. Peripheral blood biomarkers for the characterization of alloimmune reactivity after pediatric liver transplantation

    Article • Pediatric Transplantation, October 2013, Wiley

    Björn Nashan

  185. Lectures

    Article • Transplant International, October 2013, Frontiers

    Björn Nashan

  186. Wound events in kidney transplant patients receiving de novo everolimus: a pooled analysis of three randomized controlled trials

    Article • Clinical Transplantation, September 2013, Wiley

    Björn Nashan

  187. Lack of association between CTLA-4 and PDCD1 polymorphisms and acute rejection in German liver transplant recipients

    Article • Human Immunology, August 2013, Elsevier

    Björn Nashan

  188. Determination of ethyl glucuronide in hair improves evaluation of long-term alcohol abstention in liver transplant candidates

    Article • Liver International, July 2013, Wiley

    Björn Nashan

  189. Extended pancreas donor program – the EXPAND study rationale and study protocol

    Article • Transplantation Research, July 2013, Springer Science + Business Media

    Björn Nashan

  190. Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients

    Article • Clinical Transplantation, July 2013, Wiley

    Björn Nashan

  191. Presence of EpCAM‐positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma

    Article • International Journal of Cancer, June 2013, Wiley

    Björn Nashan

  192. Combined targeting of AKT and mTOR using MK‐2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma

    Article • International Journal of Cancer, May 2013, Wiley

    Björn Nashan

  193. Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib

    Article • Transplant International, May 2013, Frontiers

    Björn Nashan

  194. Combined liver-kidney transplantation for children with autosomal recessive polycystic kidney disease (ARPKD): indication and outcome

    Article • Transplant International, April 2013, Frontiers

    Björn Nashan

  195. Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection

    Article • Transplant International, March 2013, Frontiers

    Björn Nashan

  196. Reperfusion of liver graft during transplantation: techniques used in transplant centres within Eurotransplant and meta-analysis of the literature

    Article • Transplant International, March 2013, Frontiers

    Björn Nashan

  197. Distractores en preguntas de opción múltiple para estudiantes de medicina: ¿cuál es su comportamiento en un examen sumativo de altas consecuencias?

    Article • Investigación en Educación Médica, January 2013, Universidad Nacional Autonoma de Mexico

    Björn Nashan

  198. Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms

    Article • Reviews in Medical Virology, November 2012, Wiley

    Professor Vincent Emery, Björn Nashan

  199. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells

    Article • Molecular Cancer, November 2012, Springer Science + Business Media

    Björn Nashan

  200. Cognitive Functioning in Children with Biliary Atresia after Liver Transplantation

    Article • Transplantation, November 2012, Wolters Kluwer Health

    Björn Nashan

  201. Combined Liver-Kidney Transplantation for Children with Autosomal Recessive Polycystic Kidney Disease

    Article • Transplantation, November 2012, Wolters Kluwer Health

    Björn Nashan

  202. Ethyl Glucuronide Determination in Hair for Evaluation of Long-Term Alcohol Abstention in Liver Transplant Candidates

    Article • Transplantation, November 2012, Wolters Kluwer Health

    Björn Nashan

  203. Full Split Liver Transplantation - Long-Term Follow-Up of a Large Series and Its Applicability in the Recent Transplant Era

    Article • Transplantation, November 2012, Wolters Kluwer Health

    Björn Nashan

  204. Immunological Monitoring for the Detection of Allograft Rejection after Pediatric Liver Transplantation

    Article • Transplantation, November 2012, Wolters Kluwer Health

    Björn Nashan

  205. Proof of Tolerance in a Kidney Transplanted Patient 22 Years after Haploidentical Bone Marrow Transplantation of the Same Donor

    Article • Transplantation, November 2012, Wolters Kluwer Health

    Björn Nashan

  206. Psychosocial Adjustment after Pediatric Liver Transplantation: The Parentsʼ Perspective

    Article • Transplantation, November 2012, Wolters Kluwer Health

    Björn Nashan

  207. Quality of Life Up to 2 Years after Living Liver Donation - A Prospective Study

    Article • Transplantation, November 2012, Wolters Kluwer Health

    Björn Nashan

  208. Reperfusion of the Transplanted Liver: Heterogeneous Techniques in European Transplantation Centres

    Article • Transplantation, November 2012, Wolters Kluwer Health

    Björn Nashan

  209. Reperfusion of the Transplanted Liver: Heterogeneous Techniques in European Transplantation Centres

    Article • Transplantation, November 2012, Wolters Kluwer Health

    Björn Nashan

  210. The New Liver Allocation Rules in Eurotransplant - Impact on the Pediatric Recipients

    Article • Transplantation, November 2012, Wolters Kluwer Health

    Björn Nashan

  211. Wound Healing Complications and the Use of Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation

    Article • Transplantation, September 2012, Wolters Kluwer Health

    Björn Nashan

  212. Response to Comments Made by Atif on “In Vitro and In Vivo Proof of Tolerance After Two-Step Haploidentical Bone Marrow and Kidney Transplantation of the Same Donor”

    Article • Transplantation, September 2012, Wolters Kluwer Health

    Björn Nashan

  213. High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation

    Article • Transplant International, August 2012, Frontiers

    Björn Nashan

  214. Cyclosporine immunosuppression does not prevent the production of donor-specific antibody capable of mediating allograft vasculopathy

    Article • The Journal of Heart and Lung Transplantation, August 2012, Elsevier

    Björn Nashan

  215. A prospective study on living related kidney donors’ quality of life in the first year: choosing appropriate reference data

    Article • Clinical Transplantation, July 2012, Wiley

    Björn Nashan

  216. Primary Human Hepatocytes from Metabolic-Disordered Children Recreate Highly Differentiated Liver-Tissue-Like Spheroids on Alginate Scaffolds

    Article • Tissue Engineering Part A, July 2012, SAGE Publications

    Björn Nashan

  217. Review of Cytomegalovirus Infection Findings With Mammalian Target of Rapamycin Inhibitor-Based Immunosuppressive Therapy in De Novo Renal Transplant Recipients

    Article • Transplantation, June 2012, Wolters Kluwer Health

    Professor Vincent Emery, Björn Nashan

  218. No association between transmembrane protein‐tyrosine phosphatase receptor type C (PTPRC) exon A 77C>G transversion and liver transplant rejection

    Article • International Journal of Immunogenetics, April 2012, Wiley

    Björn Nashan

  219. In Vitro and In Vivo Proof of Tolerance After Two-Step Haploidentical Bone Marrow and Kidney Transplantation of the Same Donor

    Article • Transplantation, March 2012, Wolters Kluwer Health

    Björn Nashan

  220. A Prospective, Multinational Pharmacoepidemiological Study of Clinical Conversion to Sirolimus Immunosuppression after Renal Transplantation

    Article • Journal of Transplantation, January 2012, Hindawi Publishing Corporation

    Björn Nashan

  221. Hepatozelluläres Karzinom statt fokal noduläre Hyperplasie – ein Fallbericht

    Article • Viszeralmedizin, January 2012, Karger Publishers

    Björn Nashan

  222. Urinary ethyl glucuronide as a novel screening tool in patients pre- and post–liver transplantation improves detection of alcohol consumption

    Article • Hepatology, November 2011, Wolters Kluwer Health

    Björn Nashan

  223. Everolimus and Long-Term Outcomes in Renal Transplantation: Erratum

    Article • Transplantation, October 2011, Wolters Kluwer Health

    Björn Nashan

  224. Everolimus and Long-Term Outcomes in Renal Transplantation

    Article • Transplantation, August 2011, Wolters Kluwer Health

    Björn Nashan

  225. Sotrastaurin, a Novel Small Molecule Inhibiting Protein-Kinase C: Randomized Phase II Study in Renal Transplant Recipients

    Article • Arabian archaeology and epigraphy, July 2011, Elsevier

    Björn Nashan

  226. The use of everolimus in pediatric liver transplant recipients: First experience in a single center

    Article • Pediatric Transplantation, June 2011, Wiley

    Björn Nashan

  227. Immediate Postoperative Intensive Care Treatment of Pediatric Combined Liver-Kidney Transplantation: Outcome and Prognostic Factors

    Article • Transplantation, May 2011, Wolters Kluwer Health

    Björn Nashan

  228. Surgical aspects and outcome of combined liver and kidney transplantation in children

    Article • Transplant International, May 2011, Frontiers

    Björn Nashan

  229. 406 Antibody Produced in the Presence of CNI Immunosuppression Contributes to Allograft Vasculopathy

    Article • The Journal of Heart and Lung Transplantation, April 2011, Elsevier

    Björn Nashan

  230. Monitoring of Nuclear Factor of Activated T-Cell-Regulated Gene Expression in De Novo and Long-Term Liver Transplant Recipients Treated With Cyclosporine A

    Article • Therapeutic Drug Monitoring, April 2011, Wolters Kluwer Health

    Björn Nashan

  231. Superior Anatomic Visualisation of a Large Intracardiac Metastasis of a Uterine Leimyosarcoma by Cardiac MRI with Important Implications for Therapeutic Strategies

    Article • International Journal of Hematology and Oncology, March 2011, Akademi Doktorlar Yayinevi

    Björn Nashan

  232. Liver transplantation in children using organs from young paediatric donors

    Article • Transplant International, March 2011, Frontiers

    Björn Nashan

  233. Primary human hepatocytes on biodegradable poly(l-lactic acid) matrices: A promising model for improving transplantation efficiency with tissue engineering

    Article • Liver Transplantation, February 2011, Wolters Kluwer Health

    Björn Nashan

  234. Aktuelle Entwicklungen der Lebertransplantation in Deutschland: MELD-basierte Organallokation und „incentives” für Transplantationszentren

    Article • Zeitschrift für Gastroenterologie, January 2011, Thieme Publishing Group

    Björn Nashan

  235. Attention and Executive Functioning Deficits in Liver-Transplanted Children

    Article • Transplantation, December 2010, Wolters Kluwer Health

    Björn Nashan

  236. 524 Cognitive Abilities, Quality of Life and Psychosocial Burden in Livertransplanted Children and Their Families. The Project Live!R

    Article • Pediatric Research, November 2010, Springer Science + Business Media

    Björn Nashan

  237. 59 Dual targeting of mTOR and HSP90 for therapy of pancreato-biliary carcinomas

    Article • European Journal of Cancer Supplements, November 2010, Elsevier

    Björn Nashan

  238. 556 Therapeutic siRNA delivery against PKN3 improves the antineoplastic efficacy of gemcitabine in an orthotopic pancreatic cancer model

    Article • European Journal of Cancer Supplements, November 2010, Elsevier

    Björn Nashan

  239. Primary rat hepatocyte culture on 3D nanofibrous polymer scaffolds for toxicology and pharmaceutical research

    Article • Biotechnology and Bioengineering, September 2010, Wiley

    Björn Nashan

  240. Five-Year Safety and Efficacy of Belatacept in Renal Transplantation

    Article • Journal of the American Society of Nephrology, September 2010, Wolters Kluwer Health

    Björn Nashan

  241. Sirolimus addition to tacrolimus-based immunosuppression induces complete remission of post-transplant lymphoproliferative disorder in a liver transplant recipient

    Article • Transplant International, September 2010, Frontiers

    Björn Nashan

  242. Sorafenib-Induced Severe Acute Hepatitis in a Stable Liver Transplant Recipient

    Article • Transplantation, July 2010, Wolters Kluwer Health

    Björn Nashan

  243. ARE LIVER TRANSPLANTED CHILDREN MORE IMPULSIVE? ATTENTION AND EXECUTIVE FUNCTIONING AFTER PEDIATRIC LIVER TRANSPLANTATION

    Article • Transplantation, July 2010, Wolters Kluwer Health

    Björn Nashan

  244. MAINTENANCE IMMUNOSUPPRESSION WITH CNI AND EVEROLIMUS AFTER ABO INCOMPATIBLE LIVING RELATED KIDNEY TRANSPLANTATION.

    Article • Transplantation, July 2010, Wolters Kluwer Health

    Björn Nashan

  245. Localization of apoptosis proteins and lymphocyte subsets in chronic rejection of human liver allograft

    Article • Interventional Medicine and Applied Science, June 2010, Akademiai Kiado

    Björn Nashan

  246. Induction of chronic renal allograft dysfunction in a rat model with complete and exclusive MHC incompatibility

    Article • Transplant Immunology, February 2010, Elsevier

    Björn Nashan

  247. Low N-acetyltransferase 2 activity in isoniazid-associated acute hepatitis requiring liver transplantation

    Article • Transplant International, February 2010, Frontiers

    Björn Nashan

  248. The value of immunoprophylaxis for cytomegalovirus infection with intravenous immunoglobulin in pediatric liver transplant recipients receiving a low-dose immunosupressive regimen

    Article • Pediatric Transplantation, February 2010, Wiley

    Björn Nashan

  249. Everolimus-induced pneumonitis: report of the first case in a liver transplant recipient and review of treatment options

    Article • Transplant International, January 2010, Frontiers

    Björn Nashan

  250. Mental and Physical Quality of Life in Actual Living Liver Donors Versus Potential Living Liver Donors

    Article • Liver Transplantation, December 2009, Wolters Kluwer Health

    Björn Nashan

  251. Prospective Observational Study of Sirolimus as Primary Immunosuppression After Renal Transplantation

    Article • Transplantation, October 2009, Wolters Kluwer Health

    Björn Nashan

  252. Liver transplantation for fulminant hepatic failure in infancy: A single center experience

    Article • Pediatric Transplantation, October 2009, Wiley

    Björn Nashan

  253. Contribution of B Cells and Antibody to Cardiac Allograft Vasculopathy

    Article • Transplantation, August 2009, Wolters Kluwer Health

    Björn Nashan

  254. Transplantation Procedures in Children With Primary Hyperoxaluria Type 1: Outcome and Longitudinal Growth

    Article • Transplantation, May 2009, Wolters Kluwer Health

    Björn Nashan

  255. Mycophenolic Acid Exposure after Administration of Mycophenolate Mofetil in the Presence and Absence of Ciclosporin in Renal Transplant Recipients

    Article • Clinical Pharmacokinetics, May 2009, Springer Science + Business Media

    Björn Nashan

  256. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients

    Article • Liver Transplantation, February 2009, Wolters Kluwer Health

    Björn Nashan

  257. 142: The Role of Alloantibody in the Development of Cardiac Allograft Vasculopathy

    Article • The Journal of Heart and Lung Transplantation, February 2009, Elsevier

    Björn Nashan

  258. Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?

    Article • Biologics Targets & Therapy, January 2009, Dove Medical Press

    Björn Nashan

  259. Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?

    Article • Biologics Targets & Therapy, January 2009, Taylor & Francis

    Björn Nashan

  260. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?

    Article • Transplantation Reviews, January 2009, Elsevier

    Björn Nashan

  261. Is right laparoscopic donor nephrectomy right?

    Article • Surgical Endoscopy, September 2008, Springer Science + Business Media

    Björn Nashan

  262. Association of four DNA polymorphisms with acute rejection after kidney transplantation

    Article • Transplant International, September 2008, Frontiers

    Björn Nashan

  263. CD8+γδ T regulatory cells mediate kidney allograft prolongation after oral exposure to alloantigen

    Article • Transplant International, July 2008, Frontiers

    Björn Nashan

  264. Induction of chronic renal allograft injury by injection of a monoclonal antibody against a donor MHC Ib molecule in a nude rat model

    Article • Transplant Immunology, July 2008, Elsevier

    Björn Nashan

  265. Aktuelle Diagnostik der primären sklerosierenden Cholangitis*

    Article • DMW - Deutsche Medizinische Wochenschrift, March 2008, Thieme Publishing Group

    Björn Nashan

  266. Aktuelle Therapie der primären sklerosierenden Cholangitis*

    Article • DMW - Deutsche Medizinische Wochenschrift, March 2008, Thieme Publishing Group

    Björn Nashan

  267. Indications for and Outcomes After Combined Lung and Liver Transplantation: A Single-Center Experience on 13 Consecutive Cases

    Article • Transplantation, February 2008, Wolters Kluwer Health

    Professor Jens Gottlieb, Björn Nashan

  268. Renal Transplantation

    Article • Clinical Journal of the American Society of Nephrology, January 2008, Wolters Kluwer Health

    Björn Nashan

  269. Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, December 2007, New England Journal of Medicine (NEJM/MMS)

    Björn Nashan

  270. The Type of Arterial Anastomosis Influences Hepatic Hemodynamics and Overall Survival in Liver Graft Recipients

    Article • Ultraschall in der Medizin - European Journal of Ultrasound, December 2007, Thieme Publishing Group

    Björn Nashan

  271. Proliferation Signal Inhibitors in Transplantation: Questions at the Cutting Edge of Everolimus Therapy

    Article • Transplantation Proceedings, December 2007, Elsevier

    Björn Nashan

  272. Cyclosporine pharmacokinetics and blood pressure responses after conversion to once‐daily dosing in maintenance liver transplant patients

    Article • Clinical Transplantation, October 2007, Wiley

    Björn Nashan

  273. Polymorphisms of Multidrug Resistance Gene (MDR1) and Cyclosporine Absorption in De Novo Renal Transplant Patients

    Article • Transplantation, May 2007, Wolters Kluwer Health

    Björn Nashan

  274. HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration

    Article • Journal of Hepatology, April 2007, Elsevier

    Björn Nashan

  275. Cyclosporine Sparing with Mycophenolate Mofetil, Daclizumab and Corticosteroids in Renal Allograft Recipients: The CAESAR Study

    Article • Arabian archaeology and epigraphy, March 2007, Elsevier

    Björn Nashan

  276. Effects of Everolimus on Cellular and Humoral Immune Processes Leading to Chronic Allograft Nephropathy in a Rat Model with Sensitized Recipients

    Article • Transplantation, February 2007, Wolters Kluwer Health

    Björn Nashan

  277. Metabolic syndrome in liver transplant recipients: Prevalence and association with major vascular events

    Article • Liver Transplantation, January 2007, Wiley

    Vivian Charles McAlister, Björn Nashan

  278. Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Stable Maintenance Renal Transplant Patients: Pooled Results From Three International, Multicenter Studies

    Article • Transplantation Proceedings, January 2007, Elsevier

    Björn Nashan

  279. Hauttumoren transplantierter Patienten

    Article • Der Hautarzt, January 2007, Springer Science + Business Media

    Björn Nashan

  280. FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1-Year, Randomized Controlled Trial in Europe and Australasia

    Article • Arabian archaeology and epigraphy, December 2006, Elsevier

    Björn Nashan

  281. Conversion to Enteric-Coated Mycophenolate Sodium From Various Doses of Mycophenolate Mofetil: Results of a Prospective International Multicenter Trial in Maintenance Renal Transplant Patients Receiving Cyclosporine

    Article • Transplantation Proceedings, November 2006, Elsevier

    Björn Nashan

  282. MDR1 C3435T Polymorphisms Correlate With Cyclosporine Levels in De Novo Renal Recipients

    Article • Transplantation Proceedings, November 2006, Elsevier

    Björn Nashan

  283. Safety, Tolerability, and Efficacy of Everolimus in De Novo Liver Transplant Recipients: 12- and 36-Month Results

    Article • Liver Transplantation, November 2006, Wolters Kluwer Health

    Björn Nashan

  284. Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response

    Article • Transplant International, October 2006, Frontiers

    Björn Nashan

  285. Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients

    Article • Transplant International, June 2006, Frontiers

    Björn Nashan

  286. Preoperative volume calculation of the hepatic venous draining areas with multi-detector row CT in adult living donor liver transplantation: impact on surgical procedure

    Article • European Radiology, May 2006, Springer Science + Business Media

    Dr Georg Stamm, Björn Nashan

  287. Sinusoidal Obstruction Syndrome of the Liver after Hematopoietic Stem Cell Transplantation: Decision Making for Orthotopic Liver Transplantation

    Article • International Journal of Hematology, April 2006, Springer Science + Business Media

    Björn Nashan

  288. A new side effect of immunosuppression: High incidence of hearing impairment after liver transplantation

    Article • Liver Transplantation, March 2006, Wolters Kluwer Health

    Björn Nashan

  289. Acute liver failure induced by green tea extracts: Case report and review of the literature

    Article • Liver Transplantation, January 2006, Wolters Kluwer Health

    Björn Nashan

  290. Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation

    Article • Liver Transplantation, January 2006, Wolters Kluwer Health

    Björn Nashan

  291. Quality of life following living donor nephrectomy comparing classical flank incision and anterior vertical mini-incision

    Article • World Journal of Urology, September 2005, Springer Science + Business Media

    Björn Nashan

  292. Costimulation Blockade with Belatacept in Renal Transplantation

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 2005, New England Journal of Medicine (NEJM/MMS)

    Björn Nashan

  293. Chronic allograft nephropathy in athymic nude rats after adoptive transfer of primed T lymphocytes

    Article • Transplant International, August 2005, Frontiers

    Björn Nashan

  294. Use of Neoral C2 monitoring: a European consensus

    Article • Transplant International, July 2005, Frontiers

    Björn Nashan

  295. FTY720, A Novel Immunomodulator: Efficacy and Safety Results from the First Phase 2A Study in de novo Renal Transplantation

    Article • Transplantation, June 2005, Wolters Kluwer Health

    Björn Nashan

  296. Adoptive Transfer of Primed CD4+ T-Lymphocytes Induces Pattern of Chronic Allograft Nephropathy in a Nude Rat Model

    Article • Transplantation, April 2005, Wolters Kluwer Health

    Björn Nashan

  297. Antibody Induction Therapy in Renal Transplant Patients Receiving Calcineurin-Inhibitor Immunosuppressive Regimens

    Article • BioDrugs, January 2005, Springer Science + Business Media

    Björn Nashan

  298. Changes of duplex parameters and splenic size in liver transplant recipients during a long period of observation

    Article • World Journal of Gastroenterology, January 2005, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Björn Nashan

  299. Everolimus and Reduced-Exposure Cyclosporine in de novo Renal-Transplant Recipients: A Three-Year Phase II, Randomized, Multicenter, Open-Label Study

    Article • Transplantation, November 2004, Wolters Kluwer Health

    Björn Nashan

  300. Living Donor Nephrectomy: Flank Incision Versus Anterior Vertical Mini-Incision

    Article • Transplantation, November 2004, Wolters Kluwer Health

    Björn Nashan

  301. PUK8 2-HOUR POST DOSE (C2) MONITORING VERSUS TROUGH (C0) MONITORING OF NEORAL: AN ECONOMIC EVALUATION

    Article • Value in Health, November 2004, Elsevier

    Björn Nashan

  302. Update on liver transplantation using cyclosporine

    Article • Transplantation Proceedings, November 2004, Elsevier

    Björn Nashan

  303. Liver transplantation using organs from donors older than 60 years

    Article • Transplant International, September 2004, Frontiers

    Björn Nashan

  304. Platelet P-selectin and GPIIb/IIIa expression after liver transplantation and resection

    Article • Transplant International, September 2004, Frontiers

    Björn Nashan

  305. Liver transplantation using organs from donors older than 60 years

    Article • Transplant International, August 2004, Frontiers

    Björn Nashan

  306. Platelet P-selectin and GPIIb/IIIa expression after liver transplantation and resection

    Article • Transplant International, August 2004, Frontiers

    Björn Nashan

  307. Laparoscopic fenestration of posttransplant lymphoceles in children

    Article • Journal of Pediatric Surgery, August 2004, Elsevier

    Björn Nashan

  308. CO-STIMULATION BLOCKADE WITH LEA29Y IN A CALCINEURIN INHIBITOR FREE MAINTENANCE REGIMEN IN RENAL TRANSPLANT: 6-MONTH EFFICACY AND SAFETY

    Article • Transplantation, July 2004, Wolters Kluwer Health

    Björn Nashan

  309. CO-STIMULATION BLOCKADE WITH LEA29Y IN RENAL TRANSPLANT: IMPROVED RENAL FUNCTION AND CV/METABOLIC PROFILE AT 6 MONTHS COMPARED WITH CYCLOSPORINE

    Article • Transplantation, July 2004, Wolters Kluwer Health

    Björn Nashan

  310. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors

    Article • Transplant International, July 2004, Frontiers

    Björn Nashan

  311. Potential clinical implications of substitution of generic cyclosporine formulations for cyclosporine microemulsion (Neoral) in transplant recipients

    Article • European Journal of Clinical Pharmacology, June 2004, Springer Science + Business Media

    Björn Nashan

  312. RESOURCE USE AND TREATMENT COSTS AFTER KIDNEY TRANSPLANTATION: IMPACT OF DEMOGRAPHIC FACTORS, COMORBIDITIES, AND COMPLICATIONS

    Article • Transplantation, May 2004, Wolters Kluwer Health

    Björn Nashan

  313. SEROLOGIC EVIDENCE OF CHLAMYDIA PNEUMONIAE INFECTION AS A LONG-TERM PREDICTOR OF CARDIOVASCULAR DEATH IN RENAL TRANSPLANT RECIPIENTS

    Article • Transplantation, May 2004, Wolters Kluwer Health

    Björn Nashan

  314. DETECTION OF CHLAMYDIA PNEUMONIAE IN LIVER TRANSPLANT PATIENTS WITH CHRONIC ALLOGRAFT REJECTION

    Article • Transplantation, May 2004, Wolters Kluwer Health

    Dr Consolato M. Sergi, Björn Nashan

  315. Achieving adequate cyclosporine exposure in liver transplant recipients: A novel strategy for monitoring and dosing using intravenous therapy

    Article • Liver Transplantation, May 2004, Wolters Kluwer Health

    Björn Nashan

  316. Renal Allograft Allocation for Children: Are We Penalizing Children to Not Penalize Adults?

    Article • Transplantation, April 2004, Wolters Kluwer Health

    Björn Nashan

  317. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant patients: preliminary results from the Myfortic Prospective Multicenter Study

    Article • Transplantation Proceedings, March 2004, Elsevier

    Björn Nashan

  318. Severe Exacerbation of Chronic Hepatitis B after Emergence of Lamivudine Resistance in a Cirrhotic Patient: Immediate Switch to Adefovir Dipivoxil Appears to be Indicated

    Article • Zeitschrift für Gastroenterologie, February 2004, Thieme Publishing Group

    Björn Nashan

  319. 3D CT modeling of hepatic vessel architecture and volume calculation in living donated liver transplantation

    Article • European Radiology, February 2004, Springer Science + Business Media

    Dr Georg Stamm, Björn Nashan

  320. Errata

    Article • Liver Transplantation, February 2004, Wolters Kluwer Health

    Björn Nashan

  321. Long‐term outcome of liver transplantation for autoimmune hepatitis

    Article • Clinical Transplantation, January 2004, Wiley

    Björn Nashan

  322. 12 Active immunization after liver transplantation for HBV related liver disease: Failure to induce HBV-specific humoral and cellular immune responses

    Article • Journal of Hepatology, January 2004, Elsevier

    Björn Nashan

  323. Elevated plasma and urine levels of ADMA and 15()-8--PGF in end-stage liver disease

    Article • Hepatology, October 2003, Wolters Kluwer Health

    Björn Nashan

  324. Results of combined and sequential liver-kidney transplantation

    Article • Liver Transplantation, October 2003, Wolters Kluwer Health

    Björn Nashan

  325. Pharmacodynamics of Single Doses of the Novel Immunosuppressant FTY720 in Stable Renal Transplant Patients

    Article • Arabian archaeology and epigraphy, July 2003, Elsevier

    Björn Nashan

  326. Suppression of Early T-Cell Receptor-Triggered Cellular Activation by the Janus Kinase 3 Inhibitor WHI-P-1541.

    Article • Transplantation, June 2003, Wolters Kluwer Health

    Björn Nashan

  327. A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A

    Article • Clinical Therapeutics, June 2003, Elsevier

    Björn Nashan

  328. Lebendnierenspende

    Article • Der Chirurg, June 2003, Springer Science + Business Media

    Björn Nashan

  329. HBSAG level at time of olt determines hepatitis B immunoglobulin dose required for elimination of HBSAG after olt in patients with HBV cirrhosis

    Article • Journal of Hepatology, April 2003, Elsevier

    Björn Nashan

  330. Chirurgische Therapie hilärer Gallengangskarzinome (Klatskin-Tumoren)

    Article • Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie, January 2003, Thieme Publishing Group

    Björn Nashan

  331. Review of the proliferation inhibitor everolimus

    Article • Expert Opinion on Investigational Drugs, December 2002, Taylor & Francis

    Björn Nashan

  332. The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation

    Article • Transplant International, October 2002, Frontiers

    Björn Nashan

  333. Basiliximab reduces acute liver allograft rejection in pediatric patients

    Article • Transplantation Proceedings, September 2002, Elsevier

    Björn Nashan

  334. Liver transplantation for liver cirrhosis in cystic fibrosis

    Article • Transplantation Proceedings, September 2002, Elsevier

    Björn Nashan

  335. Hepatic reticuloendothelial function during parenteral nutrition including an MCT/LCT or LCT emulsion after liver transplantation - a double-blind study

    Article • Transplant International, June 2002, Frontiers

    Björn Nashan

  336. Clinical validation studies of neoral C2 monitoring: a review

    Article • Transplantation, May 2002, Wolters Kluwer Health

    Björn Nashan

  337. Long-term Safety, Tolerability and Efficacy of Daclizumab (Zenapax®) in a Two-dose Regimen in Liver Transplant Recipients

    Article • Arabian archaeology and epigraphy, May 2002, Elsevier

    Björn Nashan

  338. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation1

    Article • Transplantation, May 2002, Wolters Kluwer Health

    Björn Nashan

  339. Donor evaluation in living related liver transplantation: a new non-invasive method

    Article • Journal of Hepatology, April 2002, Elsevier

    Björn Nashan

  340. First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients

    Article • Journal of the American Society of Nephrology, April 2002, Wolters Kluwer Health

    Björn Nashan

  341. Localization of chlamydia pneumoniae by immunohistochemistry and in situ PCR in chronic liver allograft rejection with obliterative arteriopathy

    Article • Journal of Hepatology, April 2002, Elsevier

    Björn Nashan

  342. Determinants of Long-Term Graft and Patient Survival after Transplantation of Kidney and Liver

    Article • Graft, March 2002, Portico

    Björn Nashan

  343. Early Clinical Experience With a Novel Rapamycin Derivative

    Article • Therapeutic Drug Monitoring, February 2002, Wolters Kluwer Health

    Björn Nashan

  344. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: Results from a double-blind randomized placebo-controlled trial

    Article • Liver Transplantation, February 2002, Wolters Kluwer Health

    Björn Nashan

  345. Ki67, E-CADHERIN, AND p53 AS PROGNOSTIC INDICATORS OF LONG-TERM OUTCOME AFTER LIVER TRANSPLANTATION FOR METASTATIC NEUROENDOCRINE TUMORS

    Article • Transplantation, February 2002, Wolters Kluwer Health

    Björn Nashan

  346. KIDNEY TRANSPLANTATION IN CHILDREN WEIGHING LESS THAN 15 kg: DONOR SELECTION AND TECHNICAL CONSIDERATIONS

    Article • Transplantation, February 2002, Wolters Kluwer Health

    Björn Nashan

  347. Single centre experience with basiliximab in paediatric renal transplantation

    Article • Nephrology Dialysis Transplantation, February 2002, Oxford University Press (OUP)

    Björn Nashan

  348. SUCCESSFUL OUTCOME OF ACUTE GRAFT-VERSUS-HOST DISEASE IN A LIVER ALLOGRAFT RECIPIENT BY WITHDRAWAL OF IMMUNOSUPPRESSION

    Article • Transplantation, January 2002, Wolters Kluwer Health

    Björn Nashan

  349. Stellenwert der Lebertransplantation beim hepatozellulären Karzinom

    Article • Der Onkologe, December 2001, Springer Science + Business Media

    Björn Nashan

  350. Liver transplantation today

    Article • Transplantation Proceedings, November 2001, Elsevier

    Björn Nashan

  351. Successful hepatitis B reinfection prophylaxis with lamivudine and hepatitis B immune globulin in patients with positive HBV-DNA at time of liver transplantation

    Article • Transplantation Proceedings, November 2001, Elsevier

    Björn Nashan

  352. The IL2 pathway in clinical immunosuppression

    Article • Transplantation Proceedings, November 2001, Elsevier

    Björn Nashan

  353. The role of certican (everolimus, rad) in the many pathways of chronic rejection

    Article • Transplantation Proceedings, November 2001, Elsevier

    Björn Nashan

  354. CLINICAL AND SUBCLINICAL ACUTE REJECTION EARLY AFTER LIVER TRANSPLANTATION

    Article • Transplantation, September 2001, Wolters Kluwer Health

    Björn Nashan

  355. RESULTS OF 3-YEAR PHASE III CLINICAL TRIALS WITH DACLIZUMAB PROPHYLAXIS FOR PREVENTION OF ACUTE REJECTION AFTER RENAL TRANSPLANTATION1

    Article • Transplantation, September 2001, Wolters Kluwer Health

    Björn Nashan

  356. MULTICENTER TRIAL EXPLORING CALCINEURIN INHIBITORS AVOIDANCE IN RENAL TRANSPLANTATION

    Article • Transplantation, May 2001, Wolters Kluwer Health

    Björn Nashan

  357. A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation

    Article • Clinical Pharmacology & Therapeutics, April 2001, Wiley

    Björn Nashan

  358. Fast quantification method for sirolimus and its major metabolites

    Article • Transplantation Proceedings, February 2001, Elsevier

    Dr Michael Deters, Björn Nashan

  359. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study

    Article • The Lancet, February 2001, Elsevier

    Björn Nashan

  360. Interleukin-2 receptor antibodyinduced alterations of ciclosporin dose requirements in paediatric transplant recipients

    Article • The Lancet, October 2000, Elsevier

    Björn Nashan

  361. Native pyeloureterostomy after kidney transplantation: experience in 48 cases

    Article • Transplant International, September 2000, Frontiers

    Björn Nashan

  362. REDUCED ACUTE REJECTION AND SUPERIOR 1-YEAR RENAL ALLOGRAFT SURVIVAL WITH BASILIXIMAB IN PATIENTS WITH DIABETES MELLITUS1

    Article • Transplantation, September 2000, Wolters Kluwer Health

    Björn Nashan

  363. IMPROVEMENT OF ACUTE AND CHRONIC RENAL DYSFUNCTION IN LIVER TRANSPLANT PATIENTS AFTER SUBSTITUTION OF CALCINEURIN INHIBITORS BY MYCOPHENOLATE MOFETIL

    Article • Transplantation, May 2000, Wolters Kluwer Health

    Björn Nashan

  364. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis

    Article • Transplant International, April 2000, Frontiers

    Björn Nashan

  365. EXPOSURE-RESPONSE RELATIONSHIPS AND IMMUNOGENICITY OF BASILIXIMAB (SIMULECT) IN LIVER TRANSPLANTATION.

    Article • Transplantation, April 2000, Wolters Kluwer Health

    Björn Nashan

  366. SPLITTING VERSUS LIVING RELATED DONATION IN LIVER TRANSPLANTATION FOR CHILDREN.

    Article • Transplantation, April 2000, Wolters Kluwer Health

    Björn Nashan

  367. Therapeutic drug monitoring of the immunosuppressant sirolimus (rapamycin) and its major metabolites

    Article • Gastroenterology, April 2000, Elsevier

    Björn Nashan

  368. THREE YEAR OUTCOME OF THE PHASE III CLINICAL TRIALS WITH DACLIZUMAB.

    Article • Transplantation, April 2000, Wolters Kluwer Health

    Björn Nashan

  369. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis

    Article • Transplant International, March 2000, Frontiers

    Björn Nashan

  370. Prognostic relevance of proliferation and cell adhesion markers inliver transplantation for metastatic neuroendocrine tumors

    Article • Journal of Hepatology, January 2000, Elsevier

    Björn Nashan

  371. Expression patterns of integrin receptors and extracellular matrix proteins in chronic rejection of human liver allografts

    Article • Transplant Immunology, December 1999, Elsevier

    Björn Nashan

  372. The interleukin-2 inhibitors and their role in low-toxicity regimens

    Article • Transplantation Proceedings, December 1999, Elsevier

    Björn Nashan

  373. Septic shock after liver transplantation for Caroli's disease: clinical improvement after treatment with C1-esterase inhibitor

    Article • Intensive Care Medicine, September 1999, Springer Science + Business Media

    Björn Nashan

  374. Total hepatectomy and liver transplantation for metastatic neuroendocrine tumors of the pancreas - a single center experience with ten patients

    Article • Langenbeck s Archives of Surgery, August 1999, Springer Science + Business Media

    Björn Nashan

  375. ATTITUDES OF PATIENTS BEFORE AND AFTER TRANSPLANTATION TOWARDS VARIOUS ALLOGRAFTS1

    Article • Transplantation, August 1999, Wolters Kluwer Health

    Björn Nashan

  376. CYTOMEGALOVIRUS INFECTIONS AFTER TREATMENT WITH DACLIZUMAB, AN ANTI IL-2 RECEPTOR ANTIBODY, FOR PREVENTION OF RENAL ALLOGRAFT REJECTION

    Article • Transplantation, July 1999, Wolters Kluwer Health

    Björn Nashan

  377. RECURRENT CARDIOCIRCULATORY ARREST AFTER KIDNEY TRANSPLANTATION RELATED TO INTRAVENOUS METHYLPREDNISOLONE BOLUS THERAPY

    Article • Transplantation, June 1999, Wolters Kluwer Health

    Björn Nashan

  378. INCREASED INTRAGRAFT TRAIL/APO-2L GENE EXPRESSION IN RENAL AND LIVER TRANSPLANTATION

    Article • Transplantation, April 1999, Wolters Kluwer Health

    Björn Nashan

  379. ORGAN-SPECIFIC T-CELL GROWTH FACTOR AND CTL GENE ACTIVATION IN RENAL AND LIVER TRANSPLANT REJECTION

    Article • Transplantation, April 1999, Wolters Kluwer Health

    Björn Nashan

  380. PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF A TWO DOSE DACLIZUMAB REGIMEN IN LIVER TRANSPLANTATION

    Article • Transplantation, April 1999, Wolters Kluwer Health

    Björn Nashan

  381. Pregnancy in kidney transplanted patients: Fetal outcome and long term effects on graft function

    Article • Transplantation, April 1999, Wolters Kluwer Health

    Björn Nashan

  382. SOLUBLE INTERLEUKIN-2 RECEPTOR (sIL-2R) PROFILES IN KIDNEY AND LIVER TRANSPLANT PATIENTS RECEIVING BASILIXIMAB (SIMULECT)

    Article • Transplantation, April 1999, Wolters Kluwer Health

    Björn Nashan

  383. Can antibody prophylaxis allow sparing of other immunosuppressives?

    Article • Transplantation Proceedings, February 1999, Elsevier

    Björn Nashan

  384. Familial Amyloidotic Polyneuropathy: domino liver transplantation

    Article • Journal of Hepatology, February 1999, Elsevier

    Björn Nashan

  385. Peripheral Hepatojejunostomy as Palliative Treatment for Irresectable Malignant Tumors of the Liver Hilum

    Article • Annals of Surgery, February 1999, Wolters Kluwer Health

    Björn Nashan

  386. Treatment of chronic renal allograft failure by addition of mycophenolate mofetil: single-center experience in 40 patients

    Article • Transplantation Proceedings, February 1999, Elsevier

    Björn Nashan

  387. Basiliximab

    Article • Drugs, January 1999, Springer Science + Business Media

    Björn Nashan

  388. Reconstructive Surgery for Ischemic-Type Lesions at the Bile Duct Bifurcation After Liver Transplantation

    Article • Annals of Surgery, January 1999, Wolters Kluwer Health

    Björn Nashan

  389. Recurrence Patterns of Hepatocellular and Fibrolamellar Carcinoma After Liver Transplantation

    Article • Journal of Clinical Oncology, January 1999, American Society of Clinical Oncology (ASCO)

    Björn Nashan

  390. REDUCTION OF ACUTE RENAL ALLOGRAFT REJECTION BY DACLIZUMAB1

    Article • Transplantation, January 1999, Wolters Kluwer Health

    Björn Nashan

  391. Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit?

    Article • Journal of Hepatology, December 1998, Elsevier

    Björn Nashan

  392. Outcome of 22 successful pregnancies after liver transplantation

    Article • Clinical Transplantation, October 1998, Wiley

    Björn Nashan

  393. BACKGROUND AND PROGNOSTIC IMPLICATIONS OF PERIREPERFUSION TISSUE INJURIES IN HUMAN LIVER TRANSPLANTS

    Article • Transplantation, September 1998, Wolters Kluwer Health

    Björn Nashan

  394. Antibodies against the GB virus C envelope 2 protein before liver transplantation protect against GB virus C de novo infection

    Article • Hepatology, August 1998, Wolters Kluwer Health

    Björn Nashan

  395. Daclizumab: outcome of phase III trials and mechanism of action

    Article • Transplantation Proceedings, August 1998, Elsevier

    Björn Nashan

  396. Disposition and immunodynamics of basiliximab in liver allograft recipients

    Article • Clinical Pharmacology & Therapeutics, July 1998, Wiley

    Björn Nashan

  397. Ovarian-like stroma in an invasive mucinous cystadenocarcinoma of the pancreas positive for inhibin. A hint concerning its possible histogenesis

    Article • Virchows Archiv, May 1998, Springer Science + Business Media

    Björn Nashan

  398. Endoscopic Dilatation of Dominant Strictures in Primary Sclerosing Cholangitis

    Article • HPB Surgery, January 1998, Wiley

    Björn Nashan

  399. Familial amyloidotic polyneuropathy as a model for orthotopic domino liver transplantation

    Article • Journal of Hepatology, January 1998, Elsevier

    Björn Nashan

  400. Liver transplantation in patients with polycystic liver disease

    Article • Transplantation Proceedings, November 1997, Elsevier

    Björn Nashan

  401. Recurrent Immunoglobulin A Nephropathy After Renal Transplantation

    Article • Transplantation, November 1997, Wolters Kluwer Health

    Björn Nashan

  402. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients

    Article • The Lancet, October 1997, Elsevier

    Björn Nashan

  403. RENAL TRANSPLANTATION FOR PATIENTS WITH AUTOIMMUNE DISEASES

    Article • Transplantation, May 1997, Wolters Kluwer Health

    Björn Nashan

  404. Early acute rejection after hepatic graft reperfusion: Association with ischemic injury with good function, oxygenation heterogeneity, and leukocyte adhesion without aggregation

    Article • Transplantation Proceedings, February 1997, Elsevier

    Björn Nashan

  405. Outcome of kidney transplantation in patients with systemic autoimmune diseases

    Article • Transplantation Proceedings, February 1997, Elsevier

    Björn Nashan

  406. FIBROSIS IN CHRONIC REJECTION OF HUMAN LIVER ALLOGRAFTS

    Article • Transplantation, December 1996, Wolters Kluwer Health

    Björn Nashan

  407. Die Bedeutung bildgebender Verfahren für das operative Vorgehen bei Erkrankungen der Nebenniere

    Article • Acta Chirurgica Austriaca, October 1996, Springer Science + Business Media

    Björn Nashan

  408. Endoscopic Management of Biliary Tract Strictures in Primary Sclerosing Cholangitis

    Article • Endoscopy, September 1996, Thieme Publishing Group

    Björn Nashan

  409. Chronic rejection in lung allografts: immunohistological analysis of fibrogenesis

    Article • Transplant International, August 1996, Frontiers

    Björn Nashan

  410. Biliary malignancies in primary sclerosing cholangitis: Timing for liver transplantation

    Article • Hepatology, May 1996, Wolters Kluwer Health

    Björn Nashan

  411. IMMUNOPROPHYLAXIS WITH A MONOCLONAL ANTI-IL-2 RECEPTOR ANTIBODY IN LIVER TRANSPLANT PATIENTS1

    Article • Transplantation, February 1996, Wolters Kluwer Health

    Björn Nashan

  412. Early intragraft inflammatory events of liver allografts leading to chronic rejection

    Article • Transplant International, November 1995, Frontiers

    Björn Nashan

  413. Early intragraft inflammatory events of liver allografts leading to chronic rejection

    Article • Transplant International, November 1995, Frontiers

    Björn Nashan

  414. Immunological effects of the anti-IL-2 receptor monoclonal antibody BT 563 in liver allografted patients

    Article • Transplant Immunology, September 1995, Elsevier

    Björn Nashan

  415. BACKGROUNDS OF EARLY INTRAGRAFT IMMUNE ACTIVATION AND REJECTION IN LIVER TRANSPLANT RECIPIENTS

    Article • Transplantation, July 1995, Wolters Kluwer Health

    Björn Nashan

  416. Extramedullary erythropoiesis in human liver grafts

    Article • Hepatology, March 1995, Wolters Kluwer Health

    Björn Nashan

  417. Extramedullary erythropoiesis in human liver grafts*1

    Article • Hepatology, March 1995, Elsevier

    Björn Nashan

  418. Expression of cell-matrix molecules and integrin receptors in human liver grafts during chronic rejection

    Article • Transplant International, December 1994, Frontiers

    Björn Nashan

  419. Liver transplantation as an option in patients with cholangiocellular and bile duct carcinoma

    Article • January 1994, Springer Science + Business Media

    Björn Nashan

  420. PERSISTENCE OF DONOR LYMPHOCYTES IN LIVER ALLOGRAFT RECIPIENTS

    Article • Transplantation, October 1993, Wolters Kluwer Health

    Björn Nashan

  421. INTRAGRAFT IMMUNE EVENTS AFTER HUMAN LIVER TRANSPLANTATION

    Article • Transplantation, August 1992, Wolters Kluwer Health

    Björn Nashan

  422. Hemostatic studies ofex situ hepatic surgery

    Article • The Japanese Journal of Surgery, September 1991, Springer Science + Business Media

    Björn Nashan

  423. DIFFERENTIATION OF LIVER GRAFT DYSFUNCTION BY TRANSPLANT ASPIRATION CYTOLOGY

    Article • Transplantation, April 1991, Wolters Kluwer Health

    Björn Nashan

  424. Coagulation disorder during liver transplantation

    Article • Blood Coagulation & Fibrinolysis, February 1991, Wolters Kluwer Health

    Björn Nashan

  425. HIGH INCIDENCE OF MONOCLONAL IMMUNOGLOBULINS IN PATIENTS AFTER LIVER OR HEART TRANSPLANTATION

    Article • Transplantation, September 1988, Wolters Kluwer Health

    Björn Nashan

  426. [D-Met2,Pro5]enkephalinamide activates cardioinhibitory efferents in anaesthetized dogs

    Article • European Journal of Pharmacology, April 1985, Elsevier

    Björn Nashan

  427. DROPERIDOL INHIBITS CARDIAC VAGAL EFFERENTS IN DOGS

    Article • British Journal of Anaesthesia, November 1984, Elsevier

    Björn Nashan

  428. Transplant International

    Article • Transplant International, Wiley

    Björn Nashan

  429. Experience with Fourth Time Kidney Transplantation

    Article • Springer Science + Business Media

    Björn Nashan

  430. Kidney Retransplantation in Sensitized Patients: Experience with a New Immunosuppressive Protocol

    Article • Springer Science + Business Media

    Björn Nashan